Cassava Sciences Announces New Website Launch
May 28 2019 - 8:29AM
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage
biotechnology company, announced today the launch of its newly
designed website, www.CassavaSciences.com. Cassava Sciences’
new website has extensive information on Alzheimer’s disease, a key
focus of the Company’s research and development.
“Our re-designed website was developed to serve and
to communicate with our stakeholders,” said Remi Barbier, President
& CEO. “It’s also intended to convey our commitment and
strong excitement for the development and use of biomarkers and new
drugs for Alzheimer’s disease.”
Cassava Sciences recently completed a Phase 2a
safety study in Alzheimer’s disease with PTI-125, a new drug with a
novel mechanism of action. Funding for this Phase 2 study was
provided by the National Institutes of Health (NIH).
Cassava Sciences expects to announce results of its
Phase2a study in the second half of 2019, after patient data are
analyzed.
About Cassava Sciences,
Inc.Our mission is to detect and treat neurodegenerative
diseases, such as Alzheimer’s disease. Over the past ten
years, we have combined state-of-the-art technology with new
insights in neurobiology to develop novel solutions for Alzheimer’s
disease. We own worldwide development and commercial rights to our
research programs in Alzheimer’s disease, and related technology,
without royalty obligations to any third-party.
About Our Research ProgramsWe are
developing a disease-modifying treatment for patients with
Alzheimer’s disease. Our lead product candidate, PTI-125, is a
small molecule drug with a novel mechanism of action. PTI-125
stabilizes a critical protein in the brain (our drug does not seek
to clear amyloid out of the brain). In published studies, PTI-125
demonstrated both cognitive improvement and slowing of disease
progression in animal models of disease. We are currently
conducting a Phase 2 clinical program with PTI-125 in Alzheimer’s
disease, with substantial scientific & financial support from
NIH.
We are also developing a diagnostic to detect
Alzheimer’s disease with a simple blood test. In blinded studies
our investigational diagnostic, PTI-125Dx, detected >10-fold
differences between patients with Alzheimer’s and age-matched
normal controls or young cognitively intact subjects.
The underlying science for our research programs is
published in prestigious peer-reviewed technical journals,
including Journal of Neuroscience, Neurobiology of Aging, and
Neuroimmunology and Neuroinflammation. In 2018, NIH awarded
us two research grants following an in-depth, confidential review
of our science and technology. These NIH grants represent up
to $6.7 million of non-dilutive financing.
Please visit our website for more information:
www.CassavaSciences.com
About Alzheimer's
Disease Alzheimer’s disease is a progressive brain
disorder that destroys memory and thinking skills. Eventually, a
person with Alzheimer’s disease may be unable to carry out even
simple tasks. Currently, there are no drug therapies to halt
Alzheimer’s disease, much less reverse its course. Unless effective
treatments are developed soon, Alzheimer’s disease is likely to
become one of the world’s most serious health care
crises.
For More Information Contact:
Eric SchoenChief Financial OfficerCassava Sciences,
Inc.eschoen@cassavasciences.com(512) 501-2450
Note Regarding Forward-Looking
Statements: This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the "Act"). Cassava Sciences disclaims any
intent or obligation to update these forward-looking statements and
claims the protection of the Safe Harbor for forward-looking
statements contained in the Act. Examples of such statements
include, but are not limited to, statements regarding the timing of
clinical studies and the potential benefits of the Company’s
programs in Alzheimer’s disease, including our ongoing Phase II
program. The Company cautions that forward-looking statements are
inherently uncertain. Such statements are based on management's
current expectations, but actual results may differ materially due
to various factors. Such statements involve risks and
uncertainties, including, but not limited to, those risks and
uncertainties relating to the ability to demonstrate the
specificity, safety, efficacy or potential health benefits of our
product candidates and including those described in the section
entitled “Risk Factors” in Cassava’s Annual Report on Form 10-K for
the year ended December 31, 2018. Existing and prospective
investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date
hereof. Except as required by law, the Company disclaims any
intention or responsibility for updating or revising any
forward-looking statements contained in this press release.
For further information regarding these and other risks related to
our business, investors should consult our filings with the U.S.
Securities and Exchange Commission (SEC), which are available on
the SEC's website at www.sec.gov.
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Sep 2023 to Sep 2024